CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 21 target
Drug / intervention
Hydrogendrug
Likely dose
Hydrogen 500mLfrom record
Key inclusion· 7
  • ✓Male gender
  • ✓Age less than 65 years
  • ✓Diagnosis of cGVHD steroid refractory or steroid-dependent
  • ✓Steroid refractory defined as no response after Prednisone ≥1mg/kg
Key exclusion· 9
  • ✕Stable disease not well controlled by current treatment
  • ✕Pregnancy
  • ✕HIV positive status
  • ✕Severe liver impairment: serum bilirubin >2.5 mg/dl without evidence of hepatic cGVHD

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02918188
NCT02918188Phase 2RecruitingMonitorUpdated 71mo ago · Completion was 5mo ago
Slow Enrollment
Long Recruiting
Monitor
CompareCT.gov

Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent Chronic Graft-versus-host-disease

Navy General Hospital, Beijing·interventional·Posted Sep 28, 2016·Updated Jul 21, 2020

In Brief

A Phase 2 clinical trial evaluating Hydrogen for Chronic Graft-versus-host Disease. Currently recruiting, targeting 21 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

This study suggested that hydrogen has a potential as an effective and safe therapeutic agent on cGVHD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Graft-versus-host Disease
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
2016201720182019202020212022202320242025202620272028202920302031
First PostedSep 28, 2016
Enrollment StartJan 1, 2016
Primary CompletionJan 1, 2026
Study CompletionJan 1, 2031
TodayJul 2, 2026
Enrollment to primary: 10 yearsPosted 9.8 years ago

Interventions

Hydrogendrug

Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)